60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharmaceuticals enrolled the first patient in its clinical trial evaluating tafenoquine for the treatment of babesiosis, marking the start of the 2026 tick season recruitment. The randomized, double-blind, placebo-controlled trial is being conducted at five sites in the northeastern U.S. and is tracking approximately one month ahead of schedule.
Key figures
- Drug Name
- tafenoquine
- Phase Of Trial
- randomized, double-blind, placebo-controlled
- Clinical sites
- 5
- Enrollment status
- ahead of schedule by ~1 month
- Min enrollment for interim
- 24
- Expected interim analysis date
- early July 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.